Molecular therapy for Obesity-associated metabolic deficits/abnormalities: Alogliptin (Trade names: Nesina, Vipidia, Kazano, Oseni), , an anti-hyperglycemic drug in the DPP4 inhibitor class, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 5/February/2019, 5.34 am